Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Int J Infect Dis. 2018 Jan;66:26-32. doi: 10.1016/j.ijid.2017.10.024. Epub 2017 Nov 8.
The aim of this study was to develop a vaccine against schistosomiasis, which is a major challenge due to the complex lifecycle of the causative schistosome parasite.
SmKI-1 is a 16-kDa Kunitz-type protease inhibitor present in the excretory-secretory products and tegument of adult worms and eggs of Schistosoma mansoni. Two independent vaccine trials were performed in mice to determine the efficacy of rSmKI-1 in developing protective immunity.
The results obtained showed reductions of 23-33% in adult worms, 28-31% in intestinal eggs, 33-39% in faecal eggs, and 20-43% in liver eggs. Furthermore, rSmKI-1 significantly increased the production of interferon gamma, interleukin (IL)-10, and IL-6 in vaccinated mice, maintaining a Th1/Th2-type balanced protective response.
rSmKI-1 generated partial protection against schistosomiasis mansoni in the murine model of infection and could be developed as part of a combination vaccine with other vaccine candidates to provide an even more solid level of protection.
本研究旨在开发一种针对血吸虫病的疫苗，由于引起血吸虫病的寄生虫的复杂生命周期，这是一项重大挑战。
SmKI-1 是一种存在于曼氏血吸虫成虫和虫卵的排泄-分泌产物及表皮中的 16kDa Kunitz 型蛋白酶抑制剂。在小鼠中进行了两项独立的疫苗试验，以确定 rSmKI-1 在产生保护性免疫方面的功效。
研究结果显示，成虫减少了 23-33%，肠道卵减少了 28-31%，粪便卵减少了 33-39%，肝卵减少了 20-43%。此外，rSmKI-1 显著增加了接种疫苗的小鼠中干扰素 γ、白细胞介素（IL）-10 和 IL-6 的产生，维持了 Th1/Th2 型平衡的保护性反应。
rSmKI-1 在曼氏血吸虫感染的小鼠模型中产生了部分保护作用，可作为与其他候选疫苗联合使用的一部分，以提供更坚实的保护水平。
Zotero 插件